Median Technologies and CMIC HOLDINGS have signed a collaborative agreement for comprehensive clinical trial services. Together, Median and CMIC will leverage their complementary services to help biopharmaceutical companies accelerate oncology drug development in Japan, China and East Asia.
The agreement came following an onsite audit at Median’s headquarters in France late last year. Through the collaboration, CMIC will access Median’s innovative imaging technologies, services and imaging expertise. It also extends Median’s access to biopharmaceutical sponsors with clinical trials in Asia. Median and CMIC will promote and deliver their combined services to speed oncology drug development and provide innovative therapies to patients who need them.
“The agreement with CMIC, a leading CRO in Asia, is a landmark event for Median Technologies. With our enhanced technology and in-depth expertise in oncology medical image interpretation and management, we complement their offering in a key area of growth.” said Nicholas Campbell, chief commercial officer at Median Technologies.
“The collaboration with Median will further strengthen CMIC’s oncology trial capabilities. Through this cooperation, we would like to continue building more partnerships in oncology between our two companies,” said Toru Fujieda, managing director, Executive Corporate Officer of CMIC HOLDINGS.